Tapering Quviviq (Daridorexant) 50 mg
Quviviq (daridorexant) does not require a gradual taper and can be discontinued abruptly without risk of rebound insomnia or withdrawal symptoms. 1
Key Distinction: DORAs vs. Traditional Hypnotics
Daridorexant is a dual orexin receptor antagonist (DORA), which fundamentally differs from benzodiazepines and Z-drugs in its discontinuation profile. Unlike benzodiazepines and Z-drugs that require gradual tapering over weeks to months, daridorexant and other DORAs do not require special switching or deprescribing protocols. 1
Pharmacokinetic Support for Abrupt Discontinuation
The pharmacokinetic profile of daridorexant supports safe abrupt discontinuation:
- Terminal half-life of approximately 8 hours 2
- No accumulation with repeated dosing 2
- No evidence of physiological tolerance 3
- No withdrawal symptoms when abruptly discontinued 3
- No rebound insomnia upon cessation 3
Practical Discontinuation Approach
You can simply stop taking the 50 mg dose without any dose reduction. The medication will be eliminated from your system within approximately 24-40 hours (3-5 half-lives).
What to Expect After Stopping
- Your underlying insomnia symptoms may return, but this represents recurrence of the original condition, not rebound insomnia (which is a worsening beyond baseline that occurs with benzodiazepines/Z-drugs) 4
- No physical withdrawal symptoms are expected
- Sleep architecture remains unaffected 3
Important Caveat
While no taper is needed for daridorexant itself, if you are taking other sleep medications concurrently (particularly benzodiazepines or Z-drugs), those medications DO require gradual tapering with dose reductions of 10-25% each week over several weeks to months 4, 1.
Optimizing Long-Term Outcomes
Consider implementing cognitive-behavioral therapy for insomnia (CBT-I) either before or concurrent with discontinuation, as this increases rates of successful medication discontinuation and duration of abstinence from sleep medications 4.